G1 Therapeutics reports Q4 EPS (21c), consensus (27c)

Reports Q4 revenue $14.9M, consensus $13.07M. G1 ended 2023 with cash, cash equivalents, and marketable securities of $82.2M. “The strong Q4 vial volume growth of COSELA, which has continued through the beginning of 2024, highlights not only the importance of this unique drug to oncologists treating people living with extensive-stage small cell lung cancer, but also the significant addressable market still available to us as we drive continued penetration and growth,” said Jack Bailey, CEO. “Looking ahead, our primary clinical focus is on completing our ongoing trials of trilaciclib in metastatic triple negative breast cancer, including our pivotal PRESERVE 2 trial. We remain confident in the potential of trilaciclib in this trial given the robust long term survival benefit observed in prior trials and the increased statistical power for the final analysis. If successful, we would work closely with the FDA to expeditiously file for label expansion and bring this therapy to patients as quickly as possible.”